THE COST-EFFECTIVENESS OF EXENATIDE BID VERSUS INSULIN LISPRO TID AS ADD-ON THERAPY TO TITRATED INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES - AN ANALYSIS FROM THE SWEDISH HEALTH CARE PERSPECTIVE

被引：0

作者：

Gordon, J. ^{[1
]}

McEwan, P. ^{[1
]}

Sabale, U. ^{[2
]}

Kartman, B. ^{[2
]}

机构：

[1] Hlth Econ & Outcomes Res Ltd, Cardiff, S Glam, Wales

[2] AstraZeneca Nord Balt, Sodertalje, Sweden

来源：

VALUE IN HEALTH | 2014年 / 17卷 / 07期

关键词：

D O I：

10.1016/j.jval.2014.08.693

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PDB70

引用

页码：A344 / A344

页数：1

共 50 条

[31] Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
Marc Evans
Barrie Chubb
Jens Gundgaard
[J]. Diabetes Therapy, 2017, 8 : 275 - 291
[32] CLINICAL AND COST OUTCOMES OF TREATMENT WITH INSULIN GLARGINE VERSUS INSULIN DETEMIR IN INSULIN NAIVE TYPE 2 DIABETES PATIENTS: COST-EFFECTIVENESS ANALYSIS IN THE KAZAKHSTAN SETTING
Kostyuk, A.
Akanov, A.
Almadiyeva, A.
[J]. VALUE IN HEALTH, 2016, 19 (03) : A203 - A204
[33] Cost-effectiveness analysis of insulin therapy in type 2 diabetes patients comparing biphasic insulin aspart 70/30 versus insulin plargine in the Swedish setting
Ray, Joshua A.
Munro, Vicki
Brandt, Ann-Sofie
Valentine, William J.
Roze, Stephane
Foos, Volker
Lurati, Francesco
Palmer, Andrew J.
[J]. DIABETES, 2006, 55 : A558 - A558
[34] Cost-effectiveness of exenatide versus insulin glargine for the treatinent of type 2 diabetes in a UK setting: a long-term health economic study
Ray, J. A.
Secnik, K.
Yurgin, N.
Valentine, W. J.
Roze, S.
McKendrick, J.
Foos, V.
Palmer, A. J.
[J]. DIABETOLOGIA, 2006, 49 : 477 - 477
[35] COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO GLP-1 ANALOGUES AS AN ADD-ON TO INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS FROM A UK HEALTH CARE PERSPECTIVE
Charokopou, M.
Vioix, H.
Verheggen, B.
Eddowes, L. A.
Griffiths, M.
Gabriel, Z.
Tolley, K.
Sibartie, M.
[J]. VALUE IN HEALTH, 2014, 17 (07) : A347 - A347
[36] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC COMPARED WITH INSULIN GLARGINE IN THE MANAGEMENT OF TYPE 1 AND TYPE 2 DIABETES MELLITUS FROM THE SPANISH NATIONAL HEALTH SYSTEM PERSPECTIVE
Ramirez de Arellano, A.
Mezquita, P.
Darba, J.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A673 - A673
[37] Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes
Zupa, Margaret F.
Codario, Ronald A.
Smith, Kenneth J.
[J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (15) : 1133 - 1141
[38] COST-EFFECTIVENESS ANALYSIS OF LIRAGLUTIDE VERSUS INSULIN GLARGINE IN CHINESE PATIENTS WITH TYPE 2 DIABETES INSUFFICIENTLY CONTROLLED ON METFORMIN
Gu, X.
Liu, F.
Men, P.
Zhai, S.
[J]. VALUE IN HEALTH, 2018, 21 : S75 - S75
[39] Glycaemic control and hypoglycaemia in metformin-treated T2DM patients with exenatide BID vs insulin lispro TID added to titrated insulin glargine QD: the 4B trial
Wolffenbuttel, B. H. R.
Nauck, M. A.
Shaginian, R.
Malone, J.
Cleall, S.
de Vries, D.
Hoogwerf, B.
MacConell, L.
Diamant, M.
[J]. DIABETOLOGIA, 2013, 56 : S7 - S7
[40] Cost-effectiveness of insulin lispro versus regular insulin in patients with type 1 diabetes, based on severe hypoglycemia occurrence
Sacristan, J
Gomis, R
Maranes, JP
Ricart, W
Anderson, JH
Reviriego, J
[J]. DIABETES, 2000, 49 : A223 - A223

← 1 2 3 4 5 →